Viromed Medical AG to host Medical-Roundtable to discuss EUR 152.5 million distibution agreement with Asian UMECO Group on Wednesday, April 3rd, 2025 at 1:00PM CEST
Pinneberg, 02. April 2025 – Viromed Medical AG (“Viromed”, ticker: VMED; ISIN: DE000A3MQR65), a medical technology company and pioneer of cold plasma technology for applications in air disinfection, wound healing and intensive care medicine, yesterday announced the closing of an exclusive distribution agreement worth a total of EUR 152.5 million with UMECO Group (“Umeco”) a leading Asian distributor of medical devices in cosmetics and medicine based in Korea, for the commercialization of the novel cold plasma medical devices ViroCAP® and PulmoPlas® in ten Asian countries.
In this regard the Company will host an online Medical-Roundtable on Wednesday, April 3rd, 2025 at 1:00 PM CEST for investors, financial analysts and the general public. During this event, Uwe Perbandt, CEO of Viromed Medical AG, will discuss certain questions around the announced deal and provide an update on the further development of the company and its products.
To access the live Medical-Roundtable, please register via this link. Once registered, a link will be provided via email. The slide presentation and audio replay of the Medical-Roundtable will be available as of April 4, 2025 via this link.
A replay of the event and the slides will also be available via the “XXXX” page in the News section of the Company’s website at www.viromed.de.
About Viromed Medical AG:
Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of the innovative cold plasma technology for medical applications through its wholly owned subsidiary Viromed Medical GmbH. In doing so, Viromed can draw on a broad customer base in the DACH region. Viromed Medical AG aims to further advance the use of CAP in medicine in the coming years and to realize corresponding growth potential.